Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Precancerous Conditions 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Genital Neoplasms, Female 1Genital Diseases, Female 1Genital Diseases 1Female Urogenital Diseases and Pregnancy Complications 1Breast Neoplasms 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Acetic Acid × Clear all
NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Veana Therapeutics

Phase 1 Suspended
24 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡